75N98026Q00716

The contract under solicitation number 75N98026Q00716, issued by the National Cancer Institute of the National Institutes of Health, seeks to advance corrective editing research on splicing factor mutations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia through a sole source award to Moffitt Cancer Center & Research Institute. This procurement is justified under FAR 6.302-1 due to the unique and irreplaceable combination of clinical expertise, access to a large and rare patient population, and integrated infrastructure for patient-derived xenograft modeling that only Moffitt possesses. The work must be conducted within a single institutional environment to preserve specimen integrity and ensure seamless translational research from clinical evaluation through cellular manipulation and xenograft transplantation, eliminating the need for specimen transport between sites. The contract is a service-based award under NAICS code 813920, with an anticipated award date following the July 9, 2026 submission deadline, and performance will be coordinated from the contracting office in Bethesda, Maryland, though all research activities will be executed at Moffitt’s facility. No pricing details, contract type, period of performance, or payment information are specified, and no formal clause, delivery, packaging, or inspection standards are detailed beyond the overarching requirement that all work meet the specialized scientific and clinical benchmarks essential to MDS and CMML research. Submission of capability statements via email to the designated point of contact is required, with no formal proposal structure, page limits, or mandatory certifications provided, and no small business or socioeconomic set-aside applicability is enforced since this is a sole source acquisition.